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2Abstract
Dyggve-Melchior-Clausen (DMC) is a rare autosomal-recessive disorder characterized by
the association of a progressive spondylo-epi-metaphyseal dysplasia and mental retardation
ranging from mild to severe. Electron microscopy studies of both DMC chondrocytes and
fibroblasts reveal an enlarged endoplasmic reticulum network and a large number of
intracytoplasmic membranous vesicles, suggesting that DMC syndrome may be a storage
disorder. Indeed, DMC phenotype is often compared to that of type IV mucopolysaccharidosis
(Morquio disease), a lysosomal disorder due to either N-acetylgalactosamine-6-sulfatase or b-
galactosidase deficiency. To date however, the lysosomal pathway appears normal in DMC
patients and biochemical analyses failed to reveal any enzymatic deficiency or accumulated
substrate. Linkage studies using homozygosity mapping have led to the localization of the
disease-causing gene on chromosome 18q21.1. The gene was recently identified as a novel
transcript (Dym) encoding a 669 amino acid product (Dymeclin) with no known domains or
function. Sixteen different Dym mutations have now been described in 21 unrelated families (3
novel mutations are reported below) with at least 5 founder effects in Morocco, Lebanon and
Guam Island. Smith-MacCort syndrome (SMC), a rare variant of DMC syndrome without mental
retardation was shown to be allelic of DMC syndrome and to result from mutations in Dym that
would be less deleterious to the brain. The present review focuses on clinical, radiological and
cellular features and evolution of DMC/SMC syndromes and discusses them with regards to
identified Dym mutations and possible roles of the Dym gene product.
3Introduction and history
Dyggve-Melchior-Clausen syndrome was first described by H.V. Dyggve, J.C. Melchior
and J. Clausen in 1962, as a new form of dwarfism associated with mental retardation [1]. Short
trunk, barrel shaped thorax, rhizomelic limb shortening and some other clinical overlap with
Morquio disease, a skeletal dysplasia associated with mucopolysaccharidosis, led the authors to
speculate that the condition might also result from an inborn error of metabolism. However,
clinical and biochemical studies revealed symptoms such as corneal opacity, tooth anomalies,
hearing loss and urinary excretion of keratan sulfate as extra-skeletal signs belonging to the
common clinical picture specific of Morquio disease [2-5]. Cases described by Dyggve,
Melchior and Clausen then appeared clearly different from Morquio disease both because of the
absence of these associated symptoms and because of the presence of specific radiological
features and mental retardation. The name of “Dyggve-Melchior-Clausen syndrome” (DMC)
was finally attributed to this skeletal dysplasia after several additional cases allowed specific
clinical and radiological delineation of this novel entity [6-9]. At present, about 70 cases with
DMC have been documented. Clinical course and cellular features of this rare condition are now
well defined and the genetic cause of this autosomal recessive affection has been recently
elucidated.
4Clinical course and diagnosis of DMCS
Osteochondrodysplasias are a heterogeneous group of skeletal disorders due to impaired
cartilage and/or bone growth. DMC syndrome is an osteochondrodysplasia that belongs to the
sub-group of spondylo-epi-metaphyseal dysplasias (SEMDs), which includes a number of
conditions all defined by the combination of specific vertebral, epiphyseal and metaphyseal
anomalies.
DMC syndrome is clinically characterized by a short trunk dwarfism with a barrel shaped
chest, rhizomelic limb shortening, microcephaly with facial dysmorphism, coarse face, and
variable mental retardation (Fig. 1). Radiological features include misaligned spine, markedly
flattened vertebral bodies (platyspondyly) with a double-humped appearance, metaphyseal
irregularities, laterally displaced capital femoral epiphyses, and small pelvis with thickened and
lacy iliac crests (Fig. 2). The extremities are generally short and carpal bones are small and
irregular in shape (Fig. 3); the proximal bones of phalanges are also more severely affected than
the distal ones and accessory ossification centers at the distal ends of the metacarpals are
frequently seen [10-13]. In rare cases however, hands were reported to be radiologically normal
[7].
DMC is a progressive SEMD, which means that the skeletal phenotype is not obvious at
birth (Fig. 1A, 2A and 2B), although several cases where neonatal measurements were available
showed small size at birth [9]. The first manifestations of the disorder are usually recognized
between one and 18 months of age (Fig. 2C and 2E). The double-humped appearance of the
vertebral bodies and the very specific aspect of iliac crests become evident by 3-4 years of age
(Fig. 2D and 2F) and persist in adulthood (Fig. 2G). Thoracic deformities and feeding difficulties
appear and both microcephaly and statural delay become evident and increase during childhood
(Fig. 1B and 1C). Survival into adulthood is not jeopardized but the fully established phenotype
5results in a severe dwarfism with strong orthopaedic complications (Fig. 1C). The latter often
increase with age and potentially include lumbar lordosis, scoliosis, thoracic kyphosis,
subluxation of the hips, deformations of the knees and restricted joint mobility [1, 9, 13-15]. A
strong orthopaedic follow-up is therefore recommended for DMC children to manage walking
and moving difficulties and to prevent possible spinal cord compression due to atlantoaxial
instability [7].
Like the skeletal phenotype, mental retardation is a progressive feature in DMC.
Following a series of 16 affected children from 9 families ranging from 3 to 22 years of age,
head circumference was found to be normal at birth in the majority of cases (our unpublished
data). However, head circumference growth curve progressively decelerated below -3 SD in the
first two years of life and developmental delay increased. A 15 year-follow-up of the 3 cases
originally reported by Dyggve, Melchior and Clausen in 1962 also mentioned increasing mental
retardation and motor disability, further illustrating the evolution of the mental prognosis in
DMC [16].
By contrast to the skeletal phenotype, which – when fully installed - is quite clinically
homogeneous between patients, mental retardation is a variable feature in DMC. A wide
variability was noted at both intrafamilial and interfamilial levels: some children are clearly
hyperactive, displaying autistic features and no speech, while some others (even from the same
family) are able to speak and have moderate mental retardation. IQ usually varies between 25
and 65. In our series, MRI was performed on 5 children at different ages (but always before age
10) and considered normal in all cases (our unpublished data). However, anomalies of the white
matter were found once, in a 15 year-old child. Taking into account the fact that mental
retardation is a progressive feature in DMC, MRI should not be performed too early in
childhood.
Interestingly, a SEMD with similar bone changes to those of DMC but with normal
intelligence was described by Smith and McCort in 1958 and later highlighted by Spranger who
6used the term of Smith-McCort dwarfism (SMC) [10, 17]. Bone involvement in SMC and DMC
are sufficiently similar that these two conditions have been recognized as clinical variants of the
same condition. SMC syndrome illustrates the variability of mental involvement in DMC/SMC
dysplasias.
Differential Diagnosis of DMC
Developmental delay during childhood (with strong learning and speech difficulties) and
radiological appearance of both the iliac crests (hazy and lacy outlines) and the vertebral bodies
(flattened and double-waved) are very pathognomonic features of DMC/SMC, which help to
differentiate this rare condition from other SEMD. Despite the clinical arguments that let
hypothesize that DMC is a storage disorder, there are, at present, no biochemical investigations
allowing diagnostic confirmation of DMC.
The storage hypothesis
From its first description by Dyggve et al, resemblance of the syndrome with Morquio
disease led to the hypothesis that DMC may be a mucopolysaccharidosis [1]. The same group
reported a few years later that DMC lymphocytes incorporated excessive amounts of leucine and
fucose into intracellular macromolecules and that, consistent with a mucopolysaccharidosis,
abnormal urinary excretion of acid mucopolysaccharides was detected in DMC patients [18-19].
Like in Morquio disease, in which intralysosomal accumulation of keratan sulfate results from
the deficiency of one or the other of two enzymes (the N-acetylgalactosamine-6-sulfatase and the
b-D-galactosidase) [20-21], Rastogi et al also suggested the deficiency of a specific sulfatase or
7protease involved in proteoglycan processing as a biochemical cause of DMC [22]. Some other
studies have also reported biochemical anomalies in DMC, but the differences between findings
have made the situation somewhat cloudy: Engfeldt et al reported increased amount of
glucosaminoglycans in the cartilage from patients and indicated that the ability of proteoglycan
monomers to reaggregate as hyaluronic acid chains was decreased, further supporting the
hypothesis of a disturbance of proteoglycan degradation in DMC [23]. One the other hand,
Roesel et al pointed out a possible defect in peroxisomal metabolism since plasma and urine of
their DMC patient revealed increased amounts of pipecolic, phytanic and very long-chain fatty
acids  [24]. Conversely, several biochemical studies using cultured fibroblasts of DMC patients
and testing their ability to incorporate and degrade sulphated proteoglycans led to the conclusion
that these latter are normally metabolized in this cells and that DMC might not be a
mucopolysaccharidosis as previously suggested [9, 14, 25, 32]. In an attempt to detect a potential
misdegraded metabolite, our team also performed extensive analyses of fibroblasts, urine, and
leucocytes of several characterized DMC patients. Peroxysomal and lysosomal contents were
examined, lipid, carbohydrate and proteinic work up were checked, and activities of the
mitochondrial respiratory chain complexes were assayed. None of these experiments led to any
metabolic anomalies detection in DMC takings (our unpublished data). In summary, there are
still no specific biochemical tests able to confirm clinical/radiological DMC diagnostic, to date.
However, a quite specific phenotype has been described in chondrocytes of DMC patients and
may in certain circumstances help diagnosing the disorder.
Cellular phenotype of DMC
Histological analysis of the growth plate of an iliac crest biopsy from a patient with DMC
showed that both proliferating and differentiating chondrocytes were not arranged in columns as
8expected, but were instead clustered and engaged in a degenerating process in many areas [26].
A fibrous aspect of the hyaline cartilage matrix as well as many cytoplasmic inclusions and
vacuoles in resting chondrocytes were noticed. Engfeldt et al described a similar observation in
the growth plate from another diagnosed case of DMC [23] and further examined the specimen
by electron microscopy. They revealed that chondrocytes contained widened cisternae of rough
endoplasmic reticulum and vesicles coated with a smooth single-layered membrane. More
recently, the deficient columnar cell organization with chondrocyte clustering and degeneration
as well as the dilatation of rough endoplasmic reticulum were confirmed in two children with
SMC [27], demonstrating that bone changes in SMC and DMC are identical at both radiological
and cellular levels. Thus, the cellular phenotype of DMC/SMC syndrome evokes abnormal
storage and/or membrane trafficking, which specifically involve the endoplasmic reticulum
network and is therefore clearly different from that of Morquio disease in which ultrastructural
anomalies involve lysosomes [28-29]. The cellular phenotype of DMC syndrome is also visible
in a variety of cutaneous cell types such as melanocytes, keratinocytes, mastocytes,
macrophages, sweat glands [30] and in fibroblasts cultured ex-vivo from skin biopsies (Fig. 4).
Like chondrocytes, fibroblasts are highly vacuolated and display a very abundant network of
rough endoplasmic reticulum membranes. A combination of cellular ultrastructure with specific
radiological appearance of iliac crests indisputably argues in favour of DMC phenotype and may
refine, when feasible, the differential diagnosis of this condition.
Genetics of DMC
DMC was first delineated in sibs from a consanguineous union in Greenland, suggesting
a recessive mode of inheritance of the syndrome [1]. Other cases with healthy consanguinous
parents were subsequently reported [9-10, 14, 31] but no genetic study was available until 1979,
9probably because of the rarity of the syndrome. Toledo et al reported the first segregation
analysis in 23 affected sibs, confirming autosomal recessive inheritance in both DMC and SMC
[32]. A recessive X-linked mode of transmission has been considered once, in a large family in
which only males were affected [33], but the phenotype studied in this report probably is a
spondylo-epiphyseal dysplasia tarda and not a DMC case. Using a homozygosity mapping
strategy in 7 consanguinous DMC families, the faulty gene was recently mapped to a 1.8
centimorgan interval on chromosome 18q21.1 [34]. A genome-wide scan of a consanguineous
SMC family with 5 affected sibs allowed mapping of SMC to the same chromosomal region,
providing evidence that SMC and DMC dysplasias might be allelic disorders [35]. Interestingly,
the earlier observation by Spranger et al that DMC and SMC cases never occur in the same
family had led the authors to hypothesize that DMC/SMC dwarfism was a genetically
heterogeneous condition [10]. However, the study by Ehtesham et al wisely anticipated the fact
that SMC and DMC both result from different alterations of a same gene. The disease gene was
latter identified in 2003 as a predicted expressed sequence called FLJ20071/FLJ90130 which
finally proved to be a novel gene of 17 exons distributed over at least 400kb of genomic DNA
and renamed Dym [30, 36]. The initiator (AUG) and the terminator (TGA) codons were
identified in exon 2 and 17, respectively and a polyadenylation signal (AATAAA) was found
228 bp downstream of the stop codon. The Dym gene is predicted to encode Dymeclin, a 669-
amino acid protein of unknown function, which is highly conserved through species from human
to plants. The sequence of human Dymeclin is very similar to its mouse counterpart (94% amino
acid identity) and still well conserved in invertebrates (42% amino acid identity with D.
melanogaster and 37% with C. elegans).  However, a function for this protein in these species
has not yet been ascribed. In addition, Dymeclin does not share any homology with known
protein families and no obvious functional domains could be identified in its amino acid
sequence. Comparative searches suggested the presence of three to six transmembrane segments,
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a myristoyl site at the amino terminal end and a large number of dileucine motifs all along the
protein [30, 36], but these predictions remain to be ascertained at experimental level.
Dym gene mutations in DMC and SMC
El Ghouzzi et al identified 7 mutations of the Dym gene in 10 unrelated Mediterranean
DMC families from Morocco, Tunisia and Lebanon [30]. Cohn et al simultaneously reported 6
other Dym mutations in 2 SMC families from Guam Island and 3 DMC families [36]. Including
3 novel mutations reported here, 16 different Dym mutations have now been described in 21
unrelated families, which represent 37 affected patients (Table I). Consanguinity was reported in
15/21 families and in 3/6 non-consanguinous families, affected children were compound
heterozygotes. The large majority of mutations associated with DMC phenotype are predicted to
be deleterious to Dymeclin function since they introduce a premature stop codon through either
nucleotide substitutions (within exonic sequence or at splice sites) or nucleotide deletions
(inducing frameshifts). In three cases however, the alteration of Dym was of another type:
First, the adenosine deletion in the last exon of the gene (1877delA/K626N+frameshift) is
predicted to elongate the Dym gene product (extension of 49 amino acids), since the legitimate
stop codon is no longer in frame.
Second, one Portuguese patient had a homozygous G to C substitution in intron 1, 34
base pairs downstream of the first exon of Dym. This mutation has not yet been validated but the
clinical features of this patient fitted DMC features at both clinical and cellular levels.
Interestingly, this mutation occurs upstream of the initiation codon in exon 2 and could therefore
affect the 5’ region required for proper Dym transcription. Effects on the protein of both the
elongating mutation and the intronic substitution have not yet been investigated but Northern
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blot analyses using fibroblast RNAs from these patients indicated that the corresponding
transcripts are subjected to some degradation [37].
Third, Cohn et al reported a point mutation (1405A>T) in a DMC non-consanguineous
patient that predicted a N469Y missense substitution in a region highly conserved across species
(Table I). The patient was heterozygous for this substitution and carried a nonsense mutation on
the other allele [36]. This is the only missense mutation hitherto identified in DMC phenotype.
No correlation could be established between the type of DMC mutation (truncating,
elongating or missense) and the phenotypic severity. This is probably due to the fact that the
skeletal phenotype, although progressive throughout childhood, finally reaches a homogeneous
bony pattern not really distinguishable between patients. In addition, Dym mutations associated
with a DMC phenotype are likely to result in the complete absence of Dymeclin since no protein
products were detected in HeLa cells after over-expression of either a Q483X- or a N469Y-Dym
cDNA [38]. As suggested in the clinical section of this review, severity of mental retardation is
indeed a variable feature in DMC but again, no phenotype-genotype correlation is possible since
this variability also occurs in affected patients from the same family.
Cohn et al reported another missense mutation that was present in a heterozygous state
(259G>A, E87K) in two families with SMC phenotype. The E87 residue is also well conserved
during evolution although it lies in a quite divergent region of the protein, but the effect of this
substitution on the stability of the transcript and/or the protein has not been studied [36]. The
other allele bore a splice acceptor mutation 5’ of exon 8. The number of SMC cases where a
mutation of Dym was identified is as yet too low to support any phenotype-genotype correlation
between SMC and DMC but it has been proposed that SMC syndrome may result from less
deleterious Dym mutations than DMC syndrome [38]. Consistent with this hypothesis, Cohn et al
indicated that the splice mutation identified in their SMC patients induced leaky exon skipping,
suggesting that some normal Dymeclin is nevertheless produced [36]. Such permissive
transcription was not observed in a DMC case with a splice acceptor mutation 5’ of exon 4
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(family 8, see table I), where the whole transcript displayed complete deletion of exon 4 (our
unpublished data). By contrast to DMC cases, SMC patients would thus retain some residual
Dymeclin function. That a “rescue” mechanism occurs in neurons remains to be tested in order to
explain why mental retardation is never observed in SMC.
Five out of the 16 mutations hitherto reported in DMC/SMC syndromes are found in
more than one family from a common geographical area (Table I). For example the K626N
frameshift mutation was identified in 6 families all originating from Morocco, the splice acceptor
mutation 5’ of exon 12 was present in 2 Lebanese families and the SMC families from Guam
Island both bore the same E87K/splice acceptor mutation genotype. Affected individuals from
the families who share the same mutation also have part of the 18q21.1 haplotype in common,
indicating that those mutations are ancestral [34]. Ethnical and cultural customs and the relative
isolation of those populations may explain the evolutionarily cohabitation of distinct founder
effects.
Dym gene expression
Dym expression based on quantifying ESTs from various tissues indicates that the gene is
expressed in a wide range of human tissues including bone marrow, brain, heart, skeletal muscle,
pancreas, prostate, lung and kidney. Experimental approaches using RT-PCR, human multiple
tissue expression array and in situ hybridization suggest that Dym is ubiquitously expressed [37].
Northern blot analyses showed Dym transcripts as two bands of 3.1 and 5.6 kb, which both
appear as specific signals, since they were revealed with two non-overlapping probes [37].
Considering both the size of the coding sequence of Dym (2kb between the ATG and the TGA)
and the fact that the length of exon 1 is undetermined (as the transcriptional start site has not yet
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been defined), the 3.1kb could correspond to the expected size of Dym transcripts. On the other
hand, Northern blot analysis using fibroblasts RNAs from DMC patients showed that the 5.6 kb
band was shifted to 7 kb in the patient with the intronic mutation downstream of exon 1 (family
21, see table I), suggesting that the upper band is specific [37]. These data suggest that the Dym
gene is alternatively transcribed. If so, a large part of its sequence remains to be established.
Alternative transcription of Dym  may also help to explain how loss-of-function of an
ubiquitously expressed gene specifically affects bone growth and brain development. However,
the hypothesis that Dymeclin is involved in proteoglycan metabolism could also explain why the
phenotype predominantly affects cartilage and brain, since normal proteoglycan biosynthesis is
critical for correct elaboration of the extracellular matrix of these tissues [36].
Conclusion, future prospects
Identification of Dym  as the DMC-causing gene is an important step toward the
understanding of this condition. Before then, clinical complications of DMC are serious enough
to warrant prenatal diagnosis [13]. Skeletal anomalies are too mild to be detected during
intrauterine development but molecular diagnosis by direct sequencing of Dym from foetal DNA
might be an appropriate approach when the mutation is known.
The finding that SMC and DMC syndromes share identical radiographic features and
cartilage histology and are associated with mutations of the same gene support genetic
homogeneity of these conditions, unlike the prediction of Spranger et al [10]. However, some
patients with typical DMC features harbour a normal Dym sequence, although the disease gene
was found to be linked to the 18q21.1 region (our personal data). These data along the results of
Northern blot experiments suggest that a part of Dym coding sequence remains unknown.
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The absence of brain involvement in SMC syndrome implies that at least one mutant
allele encodes a protein with partial function in SMC patients, as discussed by Cohn et al [36].
This also suggests that a residual expression of Dym is sufficient for brain function but not for
proper development of the growth plate. On the other hand, overexpression of Dym in neuronal
cells would have dramatic consequences, as observed in Drosophila, where it caused embryo
death [39]. Further investigations will shed some light on the importance of Dym dosage.
The speculation that Dymeclin deficiency causes a defect in proteoglycan metabolism is
indeed the most attractive hypothesis since both the clinical course of the disease and the cellular
phenotype suggest a storage disorder that specifically affects tissues where extracellular matrix
plays an essential role. However, this would not necessarily imply that Dym loss-of-function
results in accumulation of a yet unidentified substrate. In view of the numerous membranous
vacuoles and the dilated endoplasmic reticulum in cells from DMC patients, the hypothesis of a
disturbance of membrane trafficking should be considered. Ongoing studies now aim to decipher
the localisation and the function of Dymeclin, especially with regards to intracellular processes
of protein maturation.
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Table I: Mutations in the Dym gene in DMC and SMC syndromes
Family Phenotype
Geographical
origin
Consan-
guinity
Affected
children
Nucleotide change
Aminoacid
change
Mutated exon Type of mutation Reference
1 DMC
Dominican
Republic
+ 1 48C>G Y16X 2 Nonsense
Cohn et al,
2003
2 DMC ND - 1
369T>A
1405A>T
Y132X
N469Y
5
13
Nonsense
Missense
Cohn et al,
2003
3 DMC Tunisia + 2 580C>T R194X 7 Nonsense
El Ghouzzi
et al, 2003
4 DMC Morocco + 1 610C>T R204X 7 Nonsense
El Ghouzzi
et al, 2003
5 DMC Morocco - 2
656T>G
1877delA
L219X
K626N+FSh
8
17
Nonsense
Frameshift
El Ghouzzi
et al, 2003
6 DMC Morocco + 2 1447C>T Q483X 13 Nonsense
El Ghouzzi
et al, 2003
7 DMC Morocco + 2 1447C>T Q483X 13 Nonsense This review
8 DMC Lebanon + 2 IVS 3 194-1G>A _ 5’ of exon4 Splice Acceptor This review
9 DMC Spain - 1
IVS 4 288-2A>G
IVS 7 621-2A>G
_
_
5’ of exon5
5’ of exon8
Splice Acceptor
Splice Acceptor This review
10 SMC Guam + 5
IVS 7 621-2A>G
259G>A
_
E87K
5’ of exon8
4
Splice Acceptor
Missense
Cohn et al,
2003
11 SMC Guam - 2
IVS 7 621-2A>G
259G>A
_
E87K
5’ of exon8
4
Splice Acceptor
Missense
Cohn et al,
2003
12 DMC Morocco + 3
IVS 10
1125+1G>T
_
3’ of exon10
Splice Donor
El Ghouzzi
et al, 2003
13 DMC Lebanon + 1
IVS 11
1252-1G>A
_ 5’ of exon12 Splice Acceptor
El Ghouzzi
et al, 2003
14 DMC Lebanon + 1
IVS 11
1252-1G>A
_ 5’ of exon12 Splice Acceptor
El Ghouzzi
et al, 2003
15 DMC Pakistan + 2 763delA A254A+FSh 8 Frameshift
Cohn et al,
2003
16 DMC Morocco + 3 1877delA K626N+ FSh 17 Frameshift
El Ghouzzi
et al, 2003
17 DMC Morocco + 2 1877delA K626N+ FSh 17 Frameshift
El Ghouzzi
et al, 2003
18 DMC Morocco + 1 1877delA K626N+ FSh 17 Frameshift
El Ghouzzi
et al, 2003
19 DMC Morocco + 1 1877delA K626N+ FSh 17 Frameshift This review
20 DMC Morocco - 1 1877delA K626N+ FSh 17 Frameshift This review
21 DMC Portugal - 1
G>C, 34bp
3’ of exon1
_ Intron 1 _ This review
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Legends to figures
Figure 1: clinical features and evolution of DMC syndrome
Pictures of a Moroccan patient with the K626N frameshift mutation in Dym, at the age
of one (A) and 3 (B) and of his brother at the age of 13 (C). DMC features are not
recognizable before the first year of life and then appear progressively. Short trunk
dwarfism with a barrel shaped chest and proximal limb shortening are evident at 3
years and persist throughout childhood. At 13 years of age, microcephaly is marked as
well as broad hands and flexion defects with orthopaedic complications.
 Figure 2: radiological features and evolution of DMC syndrome
Radiographs of Moroccan patients with the K626N frameshift mutation in Dym at
different ages. The skeletal phenotype is not obvious at birth but vertebrae are flattened
(A and B). At 14 months of age, platyspondyly (C) and epiphyseal dysplasia are visible
but the iliac wings still have a normal aspect (E). By 3-4 years of age, the double-
humped appearance of the vertebral bodies becomes evident (D), the acetabulae are
hypoplastic and irregular, the proximal femoral necks are short, with irregular
metaphyses and epiphyses (F). The very specific aspect of iliac crests is clearly visible
at 4 years of age (F), broadens by age 18 with a demineralised appearance (G) and
persists into adulthood.
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Figure 3: radiological features of hands in DMC
Radiographs of hands from a DMC patient at the age of 18. Note the short and broad
hands with irregular shape of metacarpal bone and phalanges.
Figure 4: cellular phenotype in fibroblasts from patients with DMC
Electron microscopy examination of primary fibroblasts from a control (B) and three
DMC patients with the intronic mutation downstream of exon 1 (A), the K626N
frameshift mutation (C) and the splice acceptor mutation upstream of exon 4 (D).
Unlike the control, DMC fibroblasts show large abnormal cytoplasmic vacuoles that
contain osmiophilic bodies (     ), a large number of phagocytosis vacuoles along the
cytoplasmic membrane (       ), and abundant granular endoplasmic reticulum (       ).
Black bars represent 0.2µm in pictures A, B, D and 0.1µm in picture C.
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